Vol 2005, No 58 (2005)

Table of Contents

Deal Trackers

Bioenvision Abstract
Business Review Editor

Research & Development

Biogen and Elan Lose Market Value as Tysabri® Withdrawn Abstract pdf
Business Review Editor

Features

Takeda and 3M Target HPV and Future Growth Abstract pdf
Business Review Editor
Vertex Opts for Avalon to Progress VX-944 Abstract pdf
Business Review Editor
Product Sale and Purchase Agreements Abstract pdf
Business Review Editor
Therapy Focus: Acne Abstract pdf
Business Review Editor

Licensing

Sosei In-Licenses Otsuka’s Urology Drug Abstract pdf
Business Review Editor
Osei Acquires Exclusive Rights to Bacterial Therapeutic from Miyarisan Abstract pdf
Business Review Editor

General

Andrx Exits the Branded Drugs Business Abstract
Business Review Editor
De Novo Pharmaceuticals Ltd Abstract
Business Review Editor

Mergers & Acquisitions

Mylan and King Terminate Merger Abstract pdf
Business Review Editor
Novartis Expands Generics Business Abstract pdf
Business Review Editor

Distribution & Marketing

Mayne Pharma and PLIVA Enter Strategic Biogeneric Partnership for EPO and G-CSF Abstract pdf
Business Review Editor

Business Commentaries

The Value of Valuations html
Fintan Walton


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.